Nasdaq Sabs News Today

HC Wainwright reiterated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The brokerage currently has a $6.00 target price on the stock. Separately, Chardan Capital reiterated a buy rating and issued a $25.00 price target on shares of SAB Biotherapeutics […]

SAB Biotherapeutics (NASDAQ:SABS – Free Report) had its target price raised by Chardan Capital from $3.00 to $25.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Separately, HC Wainwright decreased their target price on shares of SAB Biotherapeutics from $10.00 to $6.00 and set […]

SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage...

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report)’s stock price dropped 1.7% during mid-day trading on Thursday . The stock traded as low as $5.75 and last traded at $5.90. Approximately 4,952 shares traded hands during trading, a decline of 71% from the average daily volume of 17,130 shares. The stock had previously closed at […]

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report)’s stock price fell 1.7% during mid-day trading on Thursday . The company traded as low as $5.75 and last traded at $5.90. 4,952 shares changed hands during trading, a decline of 71% from the average session volume of 17,130 shares. The stock had previously closed at $6.00. […]

SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a...

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Equities researchers at HC Wainwright decreased their FY2023 earnings per share (EPS) estimates for shares of SAB Biotherapeutics in a note issued to investors on Monday, January 8th. HC Wainwright analyst E. White now anticipates that the company will earn ($4.03) per share for the year, down […]

HC Wainwright restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock, up from their previous target price of $1.00. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2023 […]

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends. Analyst Ratings This is a summary of […]

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 306,500 shares, a drop of 17.5% from the August 31st total of 371,600 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio […]